#75 - David Light: Zantac recall due to cancer concerns – what you need to know
Episode Stats
Length
1 hour and 37 minutes
Words per Minute
173.6874
Summary
David Light is the CEO of Valence Labs, an online pharmacy and analytical lab that tests and dispenses drugs for the FDA. In this episode, David and I discuss a recent petition that was filed by David's company to the FDA asking for the removal of a common drug called Zadacidine from the market.
Transcript
00:00:00.000
Hey everyone, welcome to the Peter Atiyah drive. I'm your host, Peter Atiyah. The drive
00:00:10.880
is a result of my hunger for optimizing performance, health, longevity, critical thinking, along
00:00:15.940
with a few other obsessions along the way. I've spent the last several years working
00:00:19.660
with some of the most successful top performing individuals in the world. And this podcast
00:00:23.620
is my attempt to synthesize what I've learned along the way to help you live a higher quality,
00:00:28.360
more fulfilling life. If you enjoy this podcast, you can find more information on today's episode
00:00:33.000
and other topics at peteratiyahmd.com. Hey everybody, welcome to this week's episode
00:00:43.380
of the drive. I'd like to take a couple of minutes to talk about why we don't run ads on
00:00:47.640
this podcast. If you're listening to this, you probably already know, but the two things
00:00:51.640
I care most about professionally are how to live longer and how to live better. I have
00:00:57.080
a complete fascination and obsession with this topic. I practice it professionally and
00:01:01.960
I've seen firsthand how access to information is basically all people need to make better
00:01:06.720
decisions and improve the quality of their lives. Curating and sharing this knowledge is not easy.
00:01:12.140
And even before starting the podcast, that became clear to me. The sheer volume of material published
00:01:16.960
in this space is overwhelming. I'm fortunate to have a great team that helps me continue learning
00:01:22.240
and sharing this information with you. To take one example, our show notes are in a league of their
00:01:27.700
own. In fact, we now have a full-time person that is dedicated to producing those and the feedback has
00:01:33.020
mirrored this. So all of this raises a natural question. How will we continue to fund the work
00:01:39.120
necessary to support this? As you probably know, the tried and true way to do this is to sell ads.
00:01:44.660
But after a lot of contemplation, that model just doesn't feel right to me for a few reasons.
00:01:50.240
Now, the first and most important of these is trust. I'm not sure how you could trust me if I'm
00:01:56.020
telling you about something when you know I'm being paid by the company that makes it to tell
00:02:00.320
you about it. Another reason selling ads doesn't feel right to me is because I just know myself. I
00:02:06.360
have a really hard time advocating for something that I'm not absolutely nuts for. So if I don't feel
00:02:11.740
that way about something, I don't know how I can talk about it enthusiastically. So instead of selling
00:02:16.840
ads, I've chosen to do what a handful of others have proved can work over time. And that is to
00:02:22.660
create a subscriber model for my audience. This keeps my relationship with you both simple and
00:02:28.720
honest. If you value what I'm doing, you can become a member in exchange. You'll get the benefits above
00:02:35.420
and beyond what's available for free. It's that simple. It's my goal to ensure that no matter what
00:02:41.120
level you choose to support us at, you will get back more than you give. So for example,
00:02:47.440
members will receive full access to the exclusive show notes, including other things that we plan
00:02:53.740
to build upon. These are useful beyond just the podcast, especially given the technical nature
00:02:58.780
of many of our shows. Members also get exclusive access to listen to and participate in the regular
00:03:06.120
ask me anything episodes. That means asking questions directly into the AMA portal and also
00:03:12.760
getting to hear these podcasts when they come out. Lastly, and this is something I'm really excited
00:03:17.600
about. I want my supporters to get the best deals possible on the products that I love. And as I said,
00:03:23.100
we're not taking ad dollars from anyone, but instead what I'd like to do is work with companies
00:03:27.160
who make the products that I already love and would already talk about for free and have them pass
00:03:33.440
savings on to you. Again, the podcast will remain free to all, but my hope is that many of you will
00:03:40.480
find enough value in one, the podcast itself and two, the additional content exclusive for members.
00:03:47.860
I want to thank you for taking a moment to listen to this. If you learn from and find value in the
00:03:52.680
content I produce, please consider supporting us directly by signing up for a monthly subscription.
00:03:58.200
My guest this week is David Light, the CEO of Valisher, which is an online pharmacy and analytical
00:04:04.300
laboratory that tests the drugs it dispenses. As some of you may have heard on September 13th of
00:04:10.460
this year, a citizen's petition was filed by David's company to the FDA requesting the immediate attention
00:04:17.140
to and potentially removal of a very common drug called Zantac or ranitidine from the market based on a lot
00:04:24.640
of analytical horsepower that they had thrown at it, suggesting that Zantac ranitidine in its generic
00:04:31.480
form was unstable and it decayed heavily into a carcinogen known as NDMA. The details of this,
00:04:42.240
obviously we discuss in the podcast, but they are quite staggering when you consider the magnitude at
00:04:48.160
which this decay occurs and therefore the level at which people could be exposed. Now, the purpose of
00:04:53.240
this episode, of course, is not to scare people, though in the end, I do something I rarely do,
00:04:58.820
which is make a recommendation, which is if you are playing this through the lens of standard risk
00:05:05.600
analysis, the better thing to do is to probably at least yourself stop taking this drug, even if the
00:05:12.100
FDA, which at the time of this recording has not asked for a withdrawal, either voluntary or otherwise.
00:05:19.660
It's important to note that at this time, 30 other countries, including Canada, many countries in
00:05:25.480
Europe, the Middle East have done that, have gone to the step of saying this drug is off the market
00:05:31.540
until we clarify what these issues are. In the first 20 minutes of this episode, we get into the
00:05:37.740
background and it is kind of important to understand David's background in chemistry and the background of
00:05:42.440
how this company became formed and what the impetus was for that. We then get into kind of their
00:05:47.220
first real insight that they made at the public health level, which was the discovery of a
00:05:53.320
carcinogen in a very commonly prescribed blood pressure medication called Valsartan. And in this
00:05:59.600
case, it was a contaminant, meaning it was not unique to the entire drug, but only to certain
00:06:04.780
manufacturers. However, the majority of this episode is devoted to the discussion of Zantac and
00:06:10.580
Ranitidine. I don't need to really say much more. I think the episode speaks for itself and it is
00:06:15.860
timely. And again, if you've never taken Zantac, don't care about this. Great. Might not be an
00:06:20.380
episode for you, but if you know anybody who takes this and at last check, 15 million prescriptions
00:06:26.480
of this were filled annually in the United States. And when you consider the over the counter being
00:06:31.520
easily two to three times, the number of that odds are, if you're listening to this, either you take
00:06:36.000
Zantac or know somebody who does at the very least, you'd want to pass that on to them. So without
00:06:41.760
further delay, please enjoy my conversation with David Light.
00:06:48.220
David, thank you so much for making time to speak on a Saturday evening.
00:06:54.880
If the listener is wondering why we're having this discussion on a Saturday evening,
00:06:58.080
it's in large part, I suspect, because this is kind of a timely issue. And so many of my podcasts
00:07:03.920
are scheduled out months in advance, but this was something I didn't really feel should be put off
00:07:09.300
for several months. So I thought if you were willing to talk on a Saturday night, then I would too.
00:07:16.220
Yeah, yeah. So let's spend just a couple of minutes on some background before we jump into the real
00:07:22.660
meat of this discussion. I first learned about you through a woman named Catherine Eban. Do you know
00:07:31.820
So you may know then that I interviewed her a couple of months ago, and it was honestly for me,
00:07:38.440
one of the most upsetting interviews I've ever done. I guess I haven't interviewed enough bad
00:07:43.340
guys in my life. Not that Catherine's a bad guy, but she was really talking about a story that was
00:07:47.660
for me very disheartening, but I think also for virtually every listener kind of just blew people
00:07:52.580
away. And I knew that the moment we published that podcast, which we did in probably early
00:07:57.120
September, that there was going to be a lot of questions coming out. A lot of people were going
00:08:01.400
to wonder what the implications of this were. And even just in my own little tiny bubble of a world,
00:08:06.480
which is my very small medical practice with fewer than 100 patients, the implications have
00:08:11.260
been pretty significant. We have basically changed the way we do everything in terms of we now
00:08:16.340
exclusively work with one pharmacy. That pharmacy, while not able to do what your pharmacy does,
00:08:21.500
and we'll talk about that in a moment, they're able to do something pretty darn good, which is at
00:08:25.280
our discretion and without any hesitation, they will dispense exactly which medications we want.
00:08:30.480
So branded when the patient is willing to pay for branded, and if generic, then they are able to do
00:08:37.940
what we do with them. Actually, we do the heavy lifting, I suppose, which is we go and look at the
00:08:42.460
company that makes the specific generic and look to see if there's been any interaction with the FDA.
00:08:48.020
Now that doesn't guarantee that we're safe, but I think it's reducing our odds a lot. But let's now
00:08:53.060
talk about what you do professionally and within the pharmacy space, and maybe a little bit about how you
00:08:59.640
even decided to do that. Sure. So Valisher, a company that I co-founded and the CEO of, is an online
00:09:07.600
pharmacy, but it's also attached to an analytical laboratory. So it's actually the first pharmacy,
00:09:13.700
whether online or not, that is chemically validating samples from every single batch of every single
00:09:19.860
medication that comes through our pharmacy, and screening out those that have problems, and quite a few do.
00:09:25.760
And then for our patients, only dispensing those that pass, and we also dispense it with a certificate
00:09:31.980
of analysis, very much like nutritional information. I mean, you don't buy food without looking at the
00:09:38.420
nutrition label and seeing what's in it, but where is that for your medications? So in that certificate
00:09:44.080
of analysis, we're actually giving the information of what we've actually analyzed for that particular
00:09:49.580
batch of that particular medication. Now, a lot of people might be saying, well, David, why is that
00:09:54.340
necessary? I mean, didn't the FDA already do that? Isn't the point of having the FDA that when I go
00:10:00.320
into my pharmacy and I'm dispensed my blood pressure medicine, isn't the FDA's seal on that in the same
00:10:08.580
way that the USDA's seal is on the chicken breast that I buy at the grocery store? So the FDA's seal is
00:10:15.780
on it, but I think a lot of people are rather shocked to understand that the FDA is not doing chemical
00:10:22.020
testing on the vast majority of medications that are out there. The testing that is done sometimes
00:10:27.600
in some of the batches are done by the manufacturing companies themselves, which these days are almost
00:10:33.540
entirely overseas. Eighty percent of drug products in the United States are manufactured in either India
00:10:39.360
or China, and then self-reported to the FDA. So there's obviously a lot of options for problems and
00:10:47.620
cracks in that kind of self-reported system. These days you hear a lot about self-reporting system
00:10:52.860
problems with aviation and the Boeing 737 MAX. An airplane exploding is obviously a very visible
00:10:59.360
component of something going wrong, but your medications going wrong is actually very hard
00:11:03.940
to see or to find out. And then not to mention, as you mentioned, Catherine, even before she did a very
00:11:09.520
deep study of all the fraud that goes on when there's a self-reported mechanism. So we definitely saw
00:11:17.260
that and said, this is not acceptable for how we would want pharmacy to be. Valisher actually started
00:11:23.920
with a good friend of mine from college that called me up one day and was telling me about all these
00:11:28.060
problems he was having with his anticonvulsant medications. I mean, essentially every once in a
00:11:32.060
while he'd refill it and just have this terrible month, get all these side effects and relapses
00:11:36.880
sometimes and just felt very different from how he felt otherwise. And he talked to his doctors and
00:11:42.920
he's got some great doctors and the doctors are telling him, listen, you know, this system
00:11:45.600
is problematic. 90% of what's out there these days is generic and it can be made from all over
00:11:51.100
the place. And I think as you're kind of alluding to in terms of working with one pharmacy, just
00:11:56.080
switching from generic to generic could be problematic. They're formulated differently.
00:12:01.260
They're allowed to vary in their bioequivalents by 45% from one another. So our high level solution for
00:12:08.460
this was we want to actually have medications chemically tested at the end of the supply
00:12:14.120
chain in the United States where it matters most and test them, see what's actually inside of them
00:12:20.260
and then decide if we want to actually dispense them.
00:12:23.560
Forgive me for being skeptical because while today this sounds like a great idea,
00:12:29.500
My friend Adam and I, so Adam was the one that called me up with this issue. We started
00:12:34.200
the company in 2015 and originally looking at this as a technology problem. A potential reason why
00:12:41.920
nobody's been doing this before is that the technology can be very expensive and cumbersome
00:12:47.560
and really just tailored to one or two drugs when you do this in a manufacturing plant and in pharma
00:12:52.420
companies. But if we wanted to do this in an economical way at the end of the supply chain,
00:12:57.840
there's kind of this technology gap. And so we actually spent a number of years developing
00:13:02.120
core technology, a spectroscopy based approach, essentially applying lasers to pharmaceutical
00:13:07.900
analysis so that we can do some of the most difficult and costly components of this analysis
00:13:13.900
in a much higher throughput, much easier to use way while still maintaining a high precision.
00:13:21.780
And after a couple of years of bootstrapping this whole thing and putting a lot of our
00:13:26.140
own resources into developing the technology, we achieved it. We got ISO accreditation on the
00:13:32.960
system itself. That's the International Organization for Standardization. We filed patents.
00:13:38.180
We kind of thought of this as the traditional biotech model, which is where the kind of industry
00:13:42.960
that I'm from, where a lot of the original founders of Valisher are from. And we went and talked
00:13:47.620
to the industry, the big distributors and pharmacies and manufacturers. And it was a very odd
00:13:54.840
discourse because all these major players were telling us, yeah, you know, there are a lot of
00:14:00.300
problems in the system and it looks like the problems are getting worse, but it's not our problem.
00:14:05.300
It always ended up being somebody else's problem. And we also realized that there's actually seems to
00:14:10.320
be disincentives. The established industry actually looked closer at what's on the shelves. They may not
00:14:16.980
like what they see. And so this was really around now, end of 2017, early 2018. That's when we decided,
00:14:25.480
you know, we actually have to attach this to a pharmacy. So we already had the accredited laboratory,
00:14:31.300
controlled substance licenses and everything else around a laboratory. And then we built out
00:14:35.280
the online pharmacy component. And that launched just about a year ago.
00:14:39.800
And when I was referring to my skepticism, I guess what I was really getting at was in 2015,
00:14:45.580
if you had pitched this idea to me and said, Hey, I got this idea, which is we're going to actually
00:14:50.440
test individually every single drug that gets dispensed. I would have said, gosh, that doesn't
00:14:55.580
really sound like it's a significant enough problem. I mean, there's two issues with it. Is there
00:14:59.840
enough demand for it? I would have said no. And secondly, the scalability of that strikes me as
00:15:06.440
cumbersome and difficult. So maybe to give me a tangible example, if my doctor called me in a
00:15:11.700
prescription for 90 tablets of allopurinol, 300 milligrams of allopurinol, 90 tablets to last me
00:15:18.660
for three months, would you open a batch of allopurinol that you got from your generic supplier?
00:15:24.840
Let's say that batch that you got wholesale, how many tablets would that contain?
00:15:28.220
So you're actually getting to the exact root of the business plan of how to make this economical
00:15:34.280
is that at Valisher on the pharmacy side, unlike most other pharmacies that are going to be
00:15:40.520
buying every day or every week and are kind of just constantly looking for the cheapest possible
00:15:45.580
source and therefore also not having a lot of inventory, we buy large batches. So we'll look
00:15:51.460
six months out, usually at least to buy a lot of that medication upfront. So we have a larger batch of
00:15:59.080
it so that when we sample it, when we do all of our analytics, obviously that adds some cost,
00:16:04.880
but that cost is amortized over the larger batch. So per pill that you're buying from us,
00:16:10.820
it's not adding a whole lot of cost to us, especially as we have proprietary technology
00:16:16.180
that also allows us to do this in arguably some of the cheapest possible ways. And we really optimize
00:16:21.120
for it. But we're obviously making less money than your standard big name pharmacy that's not doing
00:16:26.780
any of this. But you're seeing that a lot in the world of online pharmacy these days, that there's
00:16:32.120
all these kind of value ads that are coming out there. So whereas our competitors are working on
00:16:38.180
spending money on specialty packaging or sending chocolates with your birth control pills, that
00:16:43.880
costs money too. Instead of spending money on that, we spend money on analysis. And it obviously cuts
00:16:50.600
into the overall profit margins, but we're still able to make money as a company and offer this,
00:16:58.760
what we certainly believe is a really critical service of analysis on that batch of medication.
00:17:04.160
I don't know if you ever heard the podcast with Catherine, but I believe in that podcast,
00:17:07.660
I tell a story about sort of the first time it occurred to me that generics, there might be
00:17:12.900
something wrong with a generic. And it was several years ago. And it was a patient who
00:17:16.280
I had prescribed Crestor, which of course got filled as resuvastatin, which is not uncommon at
00:17:22.680
all. That's the generic version of Crestor. And he had previously been on atorvastatin,
00:17:27.940
the generic version of Lipitor, but there was just, there was something I didn't like.
00:17:31.420
There was a blood biomarker I didn't, I wasn't happy about. And I thought before we abandon a
00:17:36.140
statin altogether, let's give it one more try. So we put him on an equivalent dose of resuvastatin,
00:17:42.320
which is usually half the dose. So I think if he was on 40 of Lipitor or atorvastatin,
00:17:47.120
I put him down to 20 of Crestor, which got filled as resuvastatin. Eight weeks later,
00:17:51.780
I get his blood back and he's back to his baseline level of ApoB, which is the thing that I'm tracking,
00:17:58.700
suggesting he's not taking his medication at all. Now I'm not a browbeating doc. So I'm very
00:18:03.680
straightforward with my patients. I just say, Hey, did you forget to take them? Did you run out like a
00:18:08.320
month before the test or what was going on? And he said, because, and if that were the case,
00:18:12.200
he would simply say, yes, I just, my patients are very transparent. And he said, no, no, no. I take,
00:18:17.440
I take this thing religiously. And I remember scratching my head and thinking, we know that
00:18:21.060
he is statin responsive. So there's something about this batch that could be different.
00:18:26.540
So I just had my team call in and insist that we get the branded version. We got it. He took it.
00:18:34.540
It worked. I sort of forgot about it. That type of thing happened a few times over the last few
00:18:39.860
years. And then of course, reading Catherine's book, I was like, Oh my God, the lucky times are
00:18:46.260
the times when we see the drug and it has a very obvious measurable response in a biomarker. But
00:18:52.740
then there's a whole other class of drugs for which that's not entirely true. Drugs like blood pressure
00:18:56.860
medications or seizure medications or antibiotics. In fact, most drugs do not fit in the camp of
00:19:04.260
a very clear biomarker. So when you set out to do this again, based on your friend's experience,
00:19:10.320
what did you expect to find? Because at the time you guys started, Catherine hadn't done her
00:19:15.020
complete investigative watershed expose of the mass fraud coming out of India and China. So
00:19:22.840
did you think this was a needle in a haystack problem, but you just wanted to give people peace
00:19:26.940
of mind? Or did you think this was a much larger systemic issue? Actually, when Adam called me about
00:19:32.140
the issues that he was seeing himself with anticonvulsant medication, I mean, obviously I
00:19:36.000
was concerned about his own health, but for a business definitely wanted to understand,
00:19:41.260
is this something more pervasive? And I myself was not on any medications at the time. So I had no
00:19:47.640
personal experience to relate it to and figured, Hey, as a scientist myself, let's look at the literature.
00:19:54.300
And there's a lot of literature out there, especially in certain areas like anti-epileptic
00:20:00.160
drugs. You start talking to neurologists, oftentimes, especially psychiatrists that see a lot of these
00:20:06.820
issues between brand and generic, between generic and generic substitution. And I recall even back then
00:20:13.180
that one of the papers that I looked at was a Harvard medical school study that had almost 2000
00:20:19.640
patients and showed simply the act of refilling your anti-epileptic medication was associated with
00:20:26.120
an over twofold increased chance of getting a seizure. And I'm like, wow, as a scientist looking
00:20:31.000
at this, like this sounds really serious. And especially in a kind of a class of medication where
00:20:37.460
it's so clear when your medication is off, you get a seizure. But to your point, this must be happening
00:20:43.460
in all sorts of medications where it's less clear. And once you really start talking to a variety of
00:20:49.340
different doctors, you start hearing it a lot too. Like it seems like a lot of doctors have at least
00:20:53.480
suspected it as a problem or have similar stories as you talk about. I know certainly in Catherine
00:20:58.960
Eben's book, Bottle of Lies, she talks to a couple of different doctors from the Cleveland Clinic that
00:21:04.100
have seen it in heart failure medications, in diuretics. And it's very hard to actually pinpoint
00:21:10.960
the exact problem and nobody's really looking and analyzing. So what we thought in the beginning
00:21:16.340
was at the very least in certain key areas, like anti-epileptic drugs, like antidepressants and
00:21:23.520
various others that are very big markets and a lot of people seeing these issues, that at the very
00:21:29.440
least there, we could have a lot of impact and start looking. But to answer your question, did we think
00:21:36.300
the problem would be as pervasive as we're already seeing? I don't think we quite predicted just how much
00:21:43.300
we'd be finding and how quickly and how the engagement of all this has just really, really
00:21:49.500
increased in certainly in the last few years. But if you look at it, there is a huge problem with
00:21:55.320
Welbutrin and Pupropion back in the late 2000s, 2007, 2008. There's a lot of these cases that have
00:22:02.760
happened. And I think a big part of what we set out to do and what we're actually hearing from these
00:22:08.360
doctors now is that there really just wasn't much that a doctor could do. It's either brand or generic
00:22:14.320
brand. You tend to trust more, but can't obviously afford very often. And then you have generic that
00:22:21.000
there's less and less trust in, but you can afford and essentially set out to create a validated
00:22:27.320
generic. So something that has actual chemical validation behind it, and you can still afford same
00:22:34.400
price as generic that you'd be buying anywhere else. Was the business model, and more importantly,
00:22:39.420
I guess your hypothesis, that this was a problem confined to the generic market? Or did you also
00:22:45.120
intend to check branded drugs? And did you, by extension, then assume that brandeds could be
00:22:50.380
susceptible to the same problems? I think that the general thesis was that this is probably worse
00:22:55.940
in generics than in brand. However, we had nothing to really back that up. And obviously the data just
00:23:02.120
didn't exist period for these kinds of things. So our intention was always to say, we don't know
00:23:08.460
exactly where these problems are going to be from, and we're not going to make any assumptions ahead
00:23:12.200
of time. Just everything needs to be independently tested at the end of the supply chain before a
00:23:18.260
patient gets it. And David, one last question really as far as background goes. You've alluded to the
00:23:23.340
fact that you have a scientific background, but specifically what is it about your background that
00:23:26.960
allowed you to come into this space and actually innovate? I'm a molecular biologist by training
00:23:32.660
at Yale University, and I spent most of my working time in the field of DNA sequencing. So in biotech,
00:23:40.380
essentially developing complex tools for analysis of complex problems. I spent eight years most
00:23:47.520
recently at a company called Ion Torrent, where I was one of the original technology founders there and
00:23:53.180
head of chemistry R&D. And we essentially had this concept that we would sequence DNA on a microchip.
00:24:00.140
It was based on some papers that we spent millions of dollars proving was just noise. But luckily we
00:24:05.740
had some other ideas in mind and had an amazingly innovative group of people there even early on
00:24:11.960
that were able to make it work. And Ion Torrent is now the number two DNA sequencing technology in the
00:24:17.580
world. So myself and some of the other key developers, even at Ion Torrent and folks that I've worked
00:24:22.780
with before, I think we're well positioned to develop some new technology, which is, again, how we saw this
00:24:30.060
problem originally being solved as something that we can develop and then just plug into the existing
00:24:35.740
system. And that's what we started off doing and then brought in some more folks to enable the pharmacy
00:24:42.220
side to work as well. All right. So let's fast forward to a little over a year ago. It's the summer of 2018.
00:24:48.060
I actually get a call from one of my patients, the only one of my patients, who takes a medication,
00:24:52.540
called Valsartan, which is a drug called an angiotensin to receptor blocker. It's a drug that
00:24:59.400
we use in certain patients with high blood pressure. And in particular, this is a patient who all the
00:25:04.200
other boxes had been checked. Otherwise, a very healthy guy, but just couldn't get the blood pressure
00:25:08.640
where we wanted it. So here he was taking this medication and he said, hey guys, I saw something in
00:25:14.160
the paper today about some of these things being withdrawn. Should I be taking it? Tell me a little bit
00:25:23.240
So Valsartan and Losartan and various other ARB medications or Sartan medications that have been recalled
00:25:29.940
over the last year, I think are unfortunately a very clear and visible case of how the system can go wrong
00:25:38.440
and how many cracks there are in it. The fact that this global supply chain is a self-reported has a lot
00:25:45.580
of visible fraud that's happened in the past. And really what happened with Valsartan was there was
00:25:51.740
a manufacturing change to save some money in China or other places overseas that are making the variety
00:25:57.860
of these different active pharmaceutical ingredients. And by having this manufacturing change,
00:26:04.080
they were creating all sorts of impurities. So these impurities themselves being extremely
00:26:10.380
potent carcinogens. One of them that I'm sure we're going to be talking more about is NDMA,
00:26:15.240
nitrosodimethylamine. It's actually talked about as a probable human carcinogen, but you have to keep
00:26:22.080
in mind that's only because you can't ethically have a study where you give humans a carcinogen.
00:26:27.280
And the data in animals is extremely clear. It's been studied since the 1950s. NDMA is literally one
00:26:35.500
of the best studied, most potent carcinogens known to man. It's actually used as a control
00:26:41.340
to induce cancer in rats. If you're doing a clinical study and want to make absolutely sure
00:26:46.200
that a rat's going to get cancer, you give it NDMA. So this was one of the contaminants that they were
00:26:50.980
creating in this process that they obviously didn't do the proper quality controls that they
00:26:57.900
were reporting to the FDA and went all over the world. And this happened for years. It was only
00:27:03.480
detected years later, I'm sure just kind of randomly. And then as people were looking more into it and
00:27:10.480
then actually overseas countries started recalling it, eventually it was also recalled in the United
00:27:15.220
States. And it was obviously a very real problem that even continues today. So we're talking about
00:27:21.940
it in 2018, summer of 2018 is when it started. The most recent recall in Losartan, I think it was
00:27:28.720
like a week ago. And we're in October, September here of 2019. And this continues to be a pervasive
00:27:35.940
problem. Before we leave this topic and get to what we really want to talk about today, which is Zantac
00:27:40.440
and Ranitidine. What is the take-home message for patients and physicians either taking or prescribing
00:27:46.260
respectively ARBs, this class of drug? It certainly seems like the problems even there are not over,
00:27:54.640
especially the fact that there's been recent recalls even now. We at Valisher are trying to be very
00:28:00.220
proactive about this whole space. We incorporated this kind of carcinogen analysis earlier this year. I mean,
00:28:06.640
we just launched the pharmacy at the end of 2018. Towards the beginning of 2019, we added nitrosamine
00:28:13.500
assay and incorporated the FDA recommended protocol for analyzing for NDMA and other carcinogens and
00:28:21.240
impurities. And we wanted to not just look where everybody else is looking. We also looked at other
00:28:28.800
seemingly obvious places to look. So when this manufacturing change happened, what the change was
00:28:35.980
is they changed solvents. And they started using this solvent called DMF, dimethylformamide.
00:28:42.520
Can you explain to people, David, what a solvent is and why it's necessary to make a drug or do most
00:28:48.660
organic chemical reactions with solvents? Sure. So a solvent is basically something that you're
00:28:55.060
dissolving different components of chemistry into in order to make a reaction. You can think of it like
00:29:00.700
cooking. If you're going to make a soup and you want a whole bunch of things in it,
00:29:03.420
your solvent is essentially water. Or even if you're cooking an egg, for example, there's so
00:29:08.800
many different ways to cook the egg. But if you change your solvent, if you change how you're
00:29:14.940
essentially cooking that egg, although it's still an egg, all sorts of other things can happen. So
00:29:19.520
what they really did in this case of Valsartan was they might've been cooking the egg in water for a
00:29:25.140
long time. And then all of a sudden they decided to switch to oil. If you've ever fried an egg,
00:29:29.820
obviously it tastes different than if you boiled the egg. And those differences are because of all
00:29:35.160
these side reactions and side products that are happening that give it different flavors and all
00:29:40.300
sorts of different properties. But yes, it's still an egg. So they were still making Valsartan,
00:29:45.140
the key ingredient they were trying to make, but there's just so much happening on the side that
00:29:49.920
they apparently were not doing the proper controls of trying to find out what's happening there.
00:29:54.540
And NDMA, true that it's hard to look for every possible contaminant that there exists. But again,
00:30:02.400
NDMA has been well studied. It's been talked about as a problem in pharmaceuticals since at least the
00:30:07.920
seventies. So seemed like a fairly obvious thing to look for. And for us, when we started seeing all
00:30:15.560
this, of course we were going to look for NDMA and DEA and a few of these other common carcinogens that
00:30:20.980
were being talked about as by-products of this manufacturing change. But we wanted to also
00:30:26.400
look for this new solvent. I mean, if you're going to cook the egg in oil now, there might also be oil
00:30:31.380
still on that egg. And that solvent, the DMF, dimethylformamide, is itself a probable human
00:30:38.840
carcinogen. It's in the same class of a carcinogen as NDMA. And this is a categorization from the World
00:30:45.120
Health Organization and the International Organization for the Research of Cancer.
00:30:48.540
So we started looking for that too. And as soon as we started looking, we found it all over
00:30:54.860
Valsartan. We found two-thirds of the manufacturers that were making Valsartan that we actually looked
00:31:00.100
at their batches at the time had hundreds of nanograms to over 100,000 nanograms of this DMF
00:31:08.880
contaminant, which is a probable human carcinogen. And so we put together an FDA citizen petition and filed
00:31:16.340
it with the FDA saying, listen, obviously NDMA is a problem and there's other problems out there that
00:31:22.900
are certainly a good idea to continue looking at. But the solvent itself is carrying over in this
00:31:27.860
system. And whatever these companies are doing to try and clean up their process, they're apparently
00:31:32.160
not even cleaning up the solvent. So it certainly underscores the importance of checking everything
00:31:38.300
and also checking every single batch. I mean, we had manufacturers that were clean sometimes.
00:31:43.420
And then another batch had not only very high levels of DMF, even had levels of NDMA that were
00:31:49.900
violating the FDA rules. So it certainly underscores the pervasiveness of the problem and certainly in
00:31:57.860
certain areas. David, some people who are familiar with the biotech industry will have heard a term
00:32:02.180
GMP. Do you want to explain what GMP means and what the implication is for something that's
00:32:07.540
manufactured according to that standard? Yeah. GMP standing for good manufacturing practices,
00:32:12.740
anything that's under FDA purview that touches the manufacturing process is required to be under GMP.
00:32:20.320
And it's essentially hundreds of documents and systems that are in place in order to make sure that
00:32:27.720
things are very well documented and done consistently and any errors or problems or manufacturing changes
00:32:36.120
like changing over your solvent, checking for contaminants, these kinds of things are all expected
00:32:41.640
to be part of the GMP process. And when you're following the whole GMP system, then it's supposed to catch
00:32:49.460
these kinds of issues. But this is certainly a very robust system. However, it's predicated on the
00:32:56.620
concept that you're going to self-report it to the FDA and that when the FDA comes and inspects,
00:33:03.260
they're going over these documents. They're not checking the chemistry of what's actually in that
00:33:07.700
pill. Is the implication here then that, well, let me just ask the question more directly. Is there
00:33:12.860
any evidence that any of the companies involved in the production of angiotensin receptor blockers,
00:33:18.400
drugs such as Valsartan and Losartan, actually were criminally negligent? In other words,
00:33:24.180
saw that their chemical processes yielded molecules that exceeded the acceptable limits of various
00:33:31.760
toxins and failed to report it? Or do you believe the evidence suggests that rather all of this was
00:33:37.820
simply negligence and oversight? Honestly, I haven't looked at that kind of evidence well enough to
00:33:44.120
answer directly. I would say either is certainly possible. It could have been maliciously covered up by
00:33:51.480
a manufacturer, or it could just be that they were saving a few pennies per pound of these kinds of
00:33:57.880
solvents and just didn't bother to look. I definitely don't have that answer.
00:34:03.180
I don't want to get too far down this rabbit hole because like I said, what I really want to talk about
00:34:07.560
is the most timely issue here, which is the ranitidine and Zantac one. So I apologize. I keep saying
00:34:12.220
we'll get to it, but, and maybe we can park this question, but it's a broader one, which says,
00:34:16.940
why do we have the FDA if not to do this, if not to be the one to ensure that every pill that goes in
00:34:26.480
a person's body comes from a batch that has a certificate that demonstrates not only what's in
00:34:32.780
it, but what's not in it? Yeah. Look, what the FDA is there to do is a lot of things. I know we're
00:34:39.020
talking a lot about the oversight of drugs that are already in the market. Obviously a lot of what the
00:34:43.680
FDA is doing is looking at new drugs and the billion dollars that goes into developing something
00:34:49.180
new. I think the bottom line is that with limited resources, there's only so much you can do.
00:34:56.040
And a lot of what the FDA oversight is about is going through that GMP process and looking over
00:35:02.280
a bunch of paperwork that's being self-reported by the industry. And that obviously has limitations,
00:35:08.760
which honestly the FDA itself admits in a 2015 white paper direct from the FDA, A, they're saying
00:35:16.280
there's an unacceptably high occurrence of problems. And B, the FDA was saying that there's no formal
00:35:22.820
means for quality surveillance except through inspections. And inspection findings have not been
00:35:28.340
a reliable predictor of the state of quality. Those are pretty much direct quotes. So we at Valisher
00:35:35.900
and the original founders saw this as further underscoring of industry should be stepping in
00:35:42.020
and doing more. Why don't we actually analyze every single batch at the end of the supply chain?
00:35:47.460
FDA doesn't seem to have the resources to be able to do something like that,
00:35:51.160
but in the core of a new business model with some new technology and everything else,
00:35:55.260
we thought we could do it. There's more I want to talk about on that front,
00:35:58.540
but I think I'm going to save it until we get to the end of our discussion. So let's start talking
00:36:02.060
about this drug Zantac. So Zantac, the generic name for that is ranitidine has been around for
00:36:07.560
quite some time. I can't tell you how long it's been, but I certainly know it's been more than 20
00:36:11.140
years because it was among one of the most commonly prescribed drugs that I would have written
00:36:16.520
prescriptions for, for patients in medical school. It's an H2 blocker, which means that's one of,
00:36:23.180
there are three ways that you can reduce the acid secreted by the stomach. And this is one of those
00:36:28.600
ways is you can actually block the H2 receptor on the type of gastric cell that makes hydrochloric
00:36:35.400
acid. And therefore it became a very popular drug, not just for people with heartburn, but more
00:36:40.020
importantly, or at least as importantly, I suppose, even patients who didn't have heartburn, who were
00:36:44.820
undergoing hospitalization in whom one needed to reduce the burden of insult to their gastric lining.
00:36:51.140
So I don't even have the stats on how many people take ranitidine or Zantac in the United States.
00:36:58.720
The prescription ranitidine in 2016 was roughly 15 million. It was in the top 50 most prescribed
00:37:07.940
drugs. And obviously that's certainly a small percentage of the overall use being that it's
00:37:14.400
largely used over the counter by the brand Zantac or other various generics. Practically any pharmacy
00:37:21.940
that you used to go to, it's not there anymore, but pretty much every pharmacy had their own
00:37:27.180
versions and is one of the most common over the counter medications used certainly by millions of
00:37:31.920
Americans and folks over the world. Yeah. I've been fortunate in my life to not have heartburn more
00:37:36.800
than twice a year, but those two times a year, I sure took myself some ranitidine.
00:37:41.800
One other thing to mention there that was certainly a particularly high concern to us
00:37:45.920
is that the safety profile of ranitidine was considered so high that is one of the only drugs
00:37:53.300
prescribed to women while they were pregnant and given to infants for similar stomach issues.
00:38:00.200
Yes. My third child had reflux and he took a little liquid elixir of ranitidine for about three
00:38:07.680
months when he was little. And I also remember from doing my rotation in pediatrics, that was not an
00:38:12.700
uncommon thing to do. So tell me how you became interested in ranitidine. In early 2019, when we're
00:38:21.920
obviously responding to all these issues, as we've just talked about with Valsartan and other of these
00:38:27.580
blood pressure medications that had these carcinogen issues, it was obvious that we needed to incorporate
00:38:34.260
that technology and then be proactive. As we talked about, not just look for NDMA and the standard
00:38:42.320
carcinogens that others were looking for, but look for other common sense molecules and carcinogens at
00:38:48.740
the same time, but also at the same time, not just look at the blood pressure medications. So our whole
00:38:55.720
concept, of course, at Valisher is analyzing from every single batch of every single medication.
00:39:02.060
And ironically, ranitidine was pretty high in our list to go through the system because that same
00:39:07.840
friend of mine, Adam, his infant daughter also got a prescription for that elixir of ranitidine,
00:39:13.440
the syrup form. And as soon as we put it through the machine, following the standard FDA protocol at
00:39:20.480
the time, we were just floored by the results. It didn't seem possible what we were seeing on the
00:39:28.220
machine. And obviously we ran it a few more times and just consistently seeing millions of nanograms,
00:39:35.800
detection of millions when the FDA maximum permissible exposure to NDMA is 96. And again,
00:39:44.020
there's no safe level of this kind of carcinogen. The ideal level is zero and we were seeing millions
00:39:49.960
and that's how this all started. At some point, I'm sure it crosses your mind. There's a mistake here.
00:39:55.020
It's one thing if the FDA limit is 96, you're consistently seeing 100 up to 110, but you're seeing
00:40:02.180
five logarithms higher than an FDA limit. What's your self audit on that?
00:40:07.160
Gut reaction right away being a scientist is that something went wrong. Something got in there or who
00:40:13.800
knows, control went wrong perhaps and contaminated the column. The machines themselves we're talking
00:40:20.520
about don't get data wrong. I mean, these are forensic level machines. The machine specifically
00:40:26.640
is called a GCMS, a gas chromatography mass spectrometer. It's been the gold standard for
00:40:32.960
this kind of impurity analysis for decades, over 50 years. And so, you know, you start looking for
00:40:40.540
potentially human error or anything else. And I went to our chief scientific officer who brought this
00:40:46.680
obviously straight to my desk. Let's look through this system. Let's clean it. Let's run it again.
00:40:51.900
Let's run more controls. And we kept rerunning it and rerunning it and seeing the same thing.
00:40:57.400
It was very odd. But the other thing that we did at the same time was starting to look at the
00:41:01.500
literature. I mean, this is such an extreme finding. Five logarithms higher, five orders of magnitude
00:41:08.600
higher than what is even still not a good place to be. We started reading about this and there's been
00:41:16.220
literature about it for 37 years. So you're talking about it being out at least 20. The molecule was
00:41:22.500
approved in 1981. The first studies that came out that started raising concerns about NDMA and
00:41:29.100
ranitidine were published in 1982. It wasn't approved in the United States until 1983. And there was
00:41:35.640
literally decades of studies about the instability of the ranitidine molecule. There's 17 years of research
00:41:44.260
in the United States over the potential of ranitidine getting into the water supply and then forming NDMA
00:41:49.820
in drinking water. And they showed all sorts of instabilities in the molecule, reactions with chlorine,
00:41:56.140
with ozone, with all of these components that happen in a wastewater treatment plants, which are
00:42:00.620
pretty much benign for anything else. And that's when we also kind of came to the conclusion, well,
00:42:05.480
actually, if it's such an amazingly unstable molecule, perhaps it's just even breaking down
00:42:10.920
in the machinery that's meant to test these kinds of medications.
00:42:15.060
So does this mean that you were more leaning to the idea that this was not an issue specific to a
00:42:21.120
particular drug, meaning to a particular manufacturer, but rather to the drug? So when you looked at the
00:42:26.420
first sample where you see a million nanograms per dose, did I hear you correctly? A million nanograms
00:42:33.880
We were actually seeing between two and three million.
00:42:35.700
Okay. I'm guessing the first call you make once you decide this isn't a human error is somebody go
00:42:42.980
and get me branded Zantac. You got to think that this is a contaminant from the shady manufacturer
00:42:52.920
You got it exactly correct. At the same time as we're delving into the literature, we said,
00:42:57.660
okay, this is very odd about whatever was in this particular bottle, but let's just go to all of the
00:43:04.160
local pharmacies around us and buy exactly the brand Zantac. Let's buy all the various pharmacy
00:43:11.120
versions of ranitidine and test them all and get the cool mint version and the standard version and
00:43:18.880
the maximum strength and every single pill of every single manufacturer label or wherever it was coming
00:43:27.020
from, including the reference powder. So not only did we check every single bottle that we could get
00:43:32.940
our hands on at the time, we also bought the certified reference powder that's as pure as you
00:43:39.380
possibly can get it to rule out inactive ingredients or any interactions there. And even in the reference
00:43:46.000
powder, we are seeing millions of nanograms of NDMA being detected by this test.
00:43:52.880
Well, that's, I mean, that's problematic. I mean, that suggests that, let me, rather than tell you
00:44:00.000
what I think it suggests, what's your Occam's razor explanation for it at that moment? Meaning before
00:44:05.400
you do another assay, what does Occam's razor suggest is happening when branded generics alike
00:44:12.180
are containing millions of nanograms of something that should be completely absent?
00:44:18.260
I love Occam's razor and Occam's razor specifically said it's a problem with the drug. Everybody's head
00:44:24.380
has always been in this Valsartan and contamination and bad generics overseas and these kinds of things,
00:44:30.560
which are a problem too. But this was a problem must be at just a totally different level as in
00:44:37.300
the drug itself is just so incredibly unstable and not just unstable in terms of, okay, maybe you're
00:44:44.900
going to get a less potent pill. It's directly forming NDMA, the extremely potent carcinogen.
00:44:53.420
And actually one of the reasons that the specific data around these millions of nanograms was so
00:44:58.680
important, regardless of the conditions, and that's now becoming one of the discussion points,
00:45:04.400
is that there's no other way to get millions of nanograms, which is milligrams. I mean, these pills
00:45:12.080
are at 75 milligrams, 150 milligrams. So we're seeing milligrams of this carcinogen NDMA. There's
00:45:19.680
no other way that it could be there except if the molecule itself was reacting with itself and forming
00:45:27.380
it. There's no other source of nitrogen for this carcinogen, a very basic organic chemistry.
00:45:33.940
I want to double click on that for the listener who might be misunderstanding what you're saying.
00:45:37.020
This is such an important point that I'm a little floored. So a standard dose of ranitidine is 75
00:45:44.440
milligrams to 150 milligrams, correct? Correct. Okay. So, and again, just to state this for the record,
00:45:51.080
when you test a, call it 150 milligram tablet of ranitidine, you could discover, call it 1.5
00:46:00.440
million nanograms of NDMA. Yes? At least. Right. Which I didn't write it down, but I think that 1.5
00:46:08.760
million nanograms is 1.5 milligrams, right? Correct. Okay. So that means 1%, one full percent of the
00:46:18.280
supposedly active drug you're getting is a potential carcinogen. And by the way, I want to come back to
00:46:23.280
understanding the carcinogenic nature of NDMA, but let's park that for a moment. What you're saying is
00:46:28.300
just at a mass balance level, the only way you could get enough organic building block inclusive of
00:46:36.000
nitrogen to make NDMA is if you're taking some of it from the ranitidine, meaning it has to be an
00:46:42.680
almost decay or chemical reaction of the drug itself. Is that correct? Exactly. Exactly. And
00:46:49.660
from a chemistry perspective, that's extremely concerning. And I'll say one thing also that makes
00:46:56.400
it actually 10 times worse is that the NDMA molecule is a lot smaller or lighter than the
00:47:04.100
ranitidine molecule. So the molar conversion or the conversion of a ranitidine molecule into an NDMA
00:47:11.500
molecule is actually even more efficient than that 1%. The numbers are suggesting 10% or so conversion
00:47:18.600
of the ranitidine molecule into NDMA in an incredibly short period of time. So what we're talking about
00:47:28.800
in terms of this GCMS analysis is the way that it pretty much works is you have this vial where we
00:47:36.260
have a pill in it and some solvent. And then it goes into an oven, chromatography oven, where it's being
00:47:43.020
heated up. And then you sample the gas and run it through a column and then run it through a mass spec.
00:47:47.760
Long story short, you need to heat it up for a little bit to capture as many molecules as you can
00:47:53.080
that's coming off. And NDMA is a very volatile molecule. It goes into the gas. It's 15 minutes.
00:48:00.180
So it spends 15 minutes at 130 degrees Celsius, which is benign for practically any other drug that
00:48:06.480
we're looking at and is part of the FDA standard protocol. And for just these 15 minutes, which in
00:48:13.980
the chemistry world, there's very rarely do you have such a short reaction.
00:48:17.060
Yeah, that's like cooking a scrambled egg or cooking a fried egg in 10 minutes. That's pretty low temp.
00:48:22.260
Exactly. And usually if you're doing serious chemistry in a chemistry lab, you leave it for
00:48:27.180
hours or days and sometimes it requires weeks. But 15 minutes of exposure and you're getting around a
00:48:34.480
10% conversion into NDMA. That's incredible instability.
00:48:39.480
And again, the reason you're saying 10% for the listener is even though it's 1% by mass on a molar
00:48:46.020
basis, the way we actually count molecules, it's much greater.
00:48:51.160
Let's pause for a moment and talk about NDMA. I certainly have a lot of questions about this.
00:48:55.720
You've already stated the formal name of the molecule. How big a molecule is it?
00:48:59.620
It's just a few atoms, right? It's a couple nitrogens and carbon and I don't have the molecular
00:49:06.780
weight in front of me, but it's pretty small. It's a tiny little thing.
00:49:10.280
Yeah. NDMA is categorized as a small molecule. It's particularly small, even amongst small
00:49:14.540
molecules. What is the mechanism by which it causes cancer in animal models?
00:49:19.920
Yeah. So NDMA basically sticks to DNA. It sticks to DNA. It modifies it. It's what it calls
00:49:25.780
alkylates it. It also oxidizes it. Long story short, it's very bad for your DNA. And by modifying
00:49:35.220
Yeah. So sticking to DNA is not the worst thing in the world. I mean, methyl groups stick to DNA
00:49:39.180
all the time and that's called epigenetic modification, which can be quite bad, but can
00:49:44.320
also be completely inert and in some cases can be good. But this isn't just sticking to it.
00:49:49.680
It's changing the structure in the DNA in such a way that, well, presumably if it's a carcinogen,
00:49:55.060
the definition is it changes the DNA in a way that the DNA in that cell no longer responds to
00:50:00.780
appropriate cell cycle signaling. So now you have growth of a cell that can be unregulated as opposed
00:50:06.380
to regulated. How well is that documented? And in what model systems is that documented, both cell type
00:50:14.300
and in vivo versus in vitro? So the background in NDMA goes to at least the 1950s. I'll say that it's
00:50:22.520
extremely well documented in almost every clinical model, obviously other than human. In mice, rats,
00:50:30.900
cell assays, it's been heavily, heavily studied for decades. And like I was saying before, not just
00:50:37.880
studied, but also used actively as a control for inducing cancer in mice and rats.
00:50:46.140
Just to explain to the listener, in vitro means it causes cancer in a Petri dish where you take the
00:50:52.700
cells out. And if something does that, that's interesting, but it's a lot more interesting if
00:50:57.320
it can cause cancer inside the animal itself. And that's called in vivo. And that's what you just
00:51:02.360
said. Do you have a sense of what doses are necessary to induce cancer in rats?
00:51:07.720
So this part is also well studied. I don't know the exact dose, but what I can say is that the calculus
00:51:14.580
that the FDA has actually already gone through in terms of its potential effect on humans is based
00:51:21.540
on these exact kinds of animal models and studies. So during all the Valsartan and Losartan issues,
00:51:28.060
one of the statements that came from the FDA was that, well, if somebody had been taking the worst
00:51:34.440
case scenario of what they'd found, which I believe was somewhere around 17,000 nanograms or so of NDMA,
00:51:40.800
taking it consistently for years, there would be one additional cancer case in 8,000, which may sound
00:51:48.560
like a low number, but when you multiply that by the millions of people taking it, it's still thousands
00:51:54.200
of cancer cases that shouldn't have been. Obviously, there should be zero cancer cases that come from
00:52:01.220
carcinogens in your medications. And if you ask me, I'd say that number is concerning, period, to have
00:52:07.540
thousands of cancer cases. So those animal models are actually used to at least make a best guess
00:52:13.540
on what would happen in a human. And again, this is also best guess. It could be worse or could be
00:52:19.640
better. It's obviously not something you can test and to actually put inside humans.
00:52:24.780
But that doesn't seem nearly as high as some of the other carcinogens that we would expect. I mean,
00:52:31.280
there are other carcinogens that are used in laboratory testing that are guaranteed to cause cancer.
00:52:36.940
Is the difference you think the dose that in the animal studies when such agents are used,
00:52:43.820
they are used at astronomical doses, but not the same here? I mean, I'm going to tell you where I'm
00:52:49.820
going with my question in a moment so that you can think about it as you answer this question, which is
00:52:54.120
when you look at the ubiquity of Zantac use, the question is going to be where are the body bags
00:53:01.800
associated with Zantac? So before we answer that question, let's try to tease this idea out a bit
00:53:07.720
more if you don't mind. Sure. Definitely when you'd be doing a study with mice or rats and you're
00:53:14.000
trying to get them to have cancer, the dosage that those animals are getting is going to be much higher
00:53:20.680
than these trace amounts that are being found in the medications like Balsartan. I don't know
00:53:26.840
exactly what those dosages are, but I could imagine they're in the milligrams.
00:53:32.760
Interesting. So let's now talk about this epidemiologic question. I'm not a big fan of
00:53:38.360
epidemiology in general. I've sort of railed on epidemiology when it comes to nutrition, exercise,
00:53:45.480
so many things, which is not to say I think it is of no value, but I think one has to be very careful,
00:53:51.540
especially when you see sort of weak hazard ratios and try to infer causality. So when you see a hazard
00:53:59.200
ratio of 1.17, meaning there's a 17% increase in relative risk when exposed to X, and X can be
00:54:08.940
something you eat or something else. You know, I generally have a hard time with those things.
00:54:14.140
And if that is a statistically significant hazard ratio, it will have a confidence interval
00:54:18.680
that is well north of 1. So like the 95 confidence interval will not include the number 1. That's
00:54:24.300
how we sort of statistically get that. But I find epidemiology can be especially helpful when it's
00:54:28.800
not there. In other words, when epidemiology says there's no association between X and Y,
00:54:34.960
it becomes a lot easier to say there's much less likelihood that there's a causal relationship between
00:54:40.960
X and Y. So again, when you consider the ubiquity in size, 15 million prescriptions a year, plus I would
00:54:51.120
say easily three times that in over-the-counter use. So let's just call it 60 million dispensed
00:54:57.860
Xantex over-the-counter for almost 40 years. If NDMA is problematic, there should be a good collection of
00:55:06.600
body bags, shouldn't there? Definitely possible. And when we were putting the FDA citizen petition
00:55:12.000
together that we filed, we tried hard to look up. There are these epidemiological studies,
00:55:18.720
and we found one from 2004 published by the National Cancer Institute, where they looked at the antacids
00:55:27.600
at the time, the prescription antacids at the time when the study started in 1986, I believe. And they found
00:55:34.320
a link to bladder cancer when looking at those antacids, which were both reninidine and seminidine
00:55:41.180
at the time. And so it's kind of a, as far as epidemiology goes, obviously you want to look at
00:55:46.940
the individual drugs, not have them lumped together. But that was particularly concerning for us thinking
00:55:53.140
about another study that was done by Stanford University and published in 2016, which was the
00:56:01.100
only clinical study that we could find where somebody actually gave people a pill of Zantac,
00:56:06.600
and they found over 40,000 nanograms of NDMA in their urine. So we may want to talk more about that
00:56:13.280
in a second. But to answer your question about the epidemiology is essentially, it was just so assumed
00:56:19.360
that this is such an incredibly safe drug that at least as far as we could find that there just wasn't
00:56:23.640
much of that study out there. However, we have been working with a number of folks at Memorial Sloan
00:56:30.720
Kettering Cancer Center. And there's been for at least a few months now, a lot of efforts led by
00:56:36.500
Lior Bronstein to look into exactly that question. I mean, obviously, as you know, to do a full breadth
00:56:44.040
epidemiological study, I mean, these can take years, but we are looking forward to hopefully get the
00:56:49.980
initial results from Lior Bronstein and his team as soon as we can get them published in the journal.
00:56:56.460
And so what it really suggests is if there is an increase in the risk of human cancers from the use
00:57:02.020
of this, it's not going to be a la smoking. I mean, it's important, I think, for people to understand the
00:57:06.880
magnitude of risk here. In the case of cigarettes and lung cancer, the hazard ratios, depending on the
00:57:14.400
epidemiologic studies that were done, I think they varied somewhere between 8x and 14x. And I could
00:57:21.440
be off by a little bit, but I'm not off by much. So what that means is if you smoke, if you reach a
00:57:27.160
certain dose threshold of cancers, your risk of lung cancer is somewhere between 800 and 1400 times
00:57:34.440
higher than a non-smoker. In the words of one of my good friends, who's almost assuredly paraphrasing
00:57:40.860
someone else, when you don't need statistics to see the answer, that's usually a scary thing. And
00:57:46.840
that was certainly one of the cases. You didn't need complicated statistical models to tease out
00:57:52.820
the relationship between tobacco and lung cancer. Now, that does not mean, because Zantac obviously
00:58:00.080
doesn't fit that, I mean, I just, I can't imagine we wouldn't see some signal, but it could have a hazard
00:58:05.360
ratio of 2, meaning it could double your risk of a cancer. And because it's so ubiquitous, and if it's
00:58:12.580
doubling a cancer that is itself ubiquitous, that's the fear. Let me explain why to the listener, because
00:58:20.100
obviously you would get this, David. The reason that lung cancer was easy to spot from smoking is lung
00:58:27.360
cancer absent smoking is quite rare. So epidemiology is at its finest when the signal is huge,
00:58:34.960
and the thing you're studying is unusual. And that's why I believe epidemiology is almost as useful as
00:58:42.020
a warm bucket of hamster vomit when it comes to studying nutrition. Because when we study nutrition,
00:58:46.620
we're interested in the diseases of civilization, diabetes, obesity, and things like that. But the
00:58:52.380
problem is those things are so ubiquitous. I mean, there is so much of those things that it's very
00:58:58.380
difficult to pick up signals associated with lifestyle factors. So I guess what I'm trying to get at,
00:59:04.280
and feel free to disagree with me. I'd like for you to disagree or refine my thinking,
00:59:08.240
but I'm trying to make sense of this on two levels. One, how big a problem is this? And two,
00:59:15.220
what are our blind spots? I think you're basically saying we don't know how big a problem this is,
00:59:19.740
and that's the fair answer because the study hasn't been done. We haven't looked at the cases and the
00:59:24.520
controls, meaning the people who have taken it and the people who haven't. But the magnitude problem
00:59:29.100
and the blind spot problem really come down to, we will not know the answer until we figure out
00:59:34.920
which type of cancer is. Because if it increases the risk of a very rare cancer, I suspect it would
00:59:40.660
have shown up. I just think if there was a huge uptick from 1980 until today of some very rare cancer,
00:59:48.440
that would be a lot easier to point to an environmental contaminant such as a drug.
00:59:53.800
But if it's increasing the risk of breast cancer and prostate cancer, which are large cancers to
01:00:00.800
begin with, it would be harder. Do you agree with my assessment? I know you're not an epidemiologist,
01:00:04.980
but you're a clever guy and you've thought a lot about this and you've thought about it more than
01:00:08.220
I have. Well, I think it's going to be a very interesting conversation to get back to when the
01:00:13.460
results are published. And I will say that the big problem I think that's certainly underscored with
01:00:20.880
this ranitidine issue is that just nobody was looking. You could argue that how would they
01:00:25.640
have known where to look, which I can also point towards lots of studies and information of should
01:00:32.840
have been looking at NDMA. But nobody was obviously looking for the NDMA before and nobody's been looking
01:00:38.640
at the epidemiology before. There have been a number of rare cancers that have gone up that have been
01:00:43.820
unexplained, some of them starting in the 1980s. So let's defer that question for when there's more
01:00:51.040
data, of course. And I think this is something that is going to take years to really get down to
01:00:57.680
what is the total impact for real. But I can't imagine it's going to be zero. And anything greater
01:01:05.100
than zero multiplied by the millions of people taking it for 40 years nearly is a tragedy.
01:01:11.360
Especially when you consider that there are no shortage of substitutes that are equally efficacious,
01:01:17.580
if not better. I mean, that I think comes down to, it's one thing if this were the only drug out
01:01:23.520
there that could treat patients with HIV, in which case you have to weigh out the benefits of a drug
01:01:29.300
versus the costs. But when we're talking about reducing gastric acid, which again, there are more
01:01:35.140
drugs in that category than I can certainly count, it begs the question why. Now, I want to go back to
01:01:40.320
something you said. So you brought up the study by Zhang and Mitch in 2016 at Stanford. I never heard
01:01:46.380
of that study until I started looking into this Zantac ranitidine story. Presumably, you hadn't
01:01:53.400
either until you made your discovery and went back. Why did the Zhang and Mitch article not get more
01:01:59.840
attention given the largely accepted carcinogenic nature of NDMA and the, I mean, staggering nature of
01:02:07.160
the study. If I recall the study, one pill, 150 milligrams given to subjects overnight who had been
01:02:12.880
not taking it before and you just collected the urine and you found, I don't know, was it 40,000
01:02:18.540
nanograms of NDMA? Right. Over 40,000 nanograms in urine, which in and of itself sounds really bad and
01:02:28.040
obviously it is, but it's actually at least a hundred times worse because the renal clearance of NDMA,
01:02:35.120
so how much NDMA actually makes it into the urine, is that often 1% or less. And that's because
01:02:42.900
NDMA sticks to DNA and your body is full of DNA and it's reacting all over your body. And so very
01:02:50.000
little of it is actually expected to make it to the urine. So really what those results were suggesting
01:02:56.520
is that somewhere around 4 million or millions of nanograms of NDMA are being exposed in your body,
01:03:05.040
with a single pill of Zantac. And they were using the brand Zantac in that particular study,
01:03:10.820
which again, loops back into our results that we were seeing at the lab conditions, also of the
01:03:16.760
potential of this molecule to form millions of nanograms. So totally agree with you. It was an
01:03:22.260
extremely eye-opening study. And to go back to when we at Valisher were originally finding this
01:03:29.180
problem and Corey Kuchera, our chief scientific officer, brought it to my desk and we started
01:03:34.960
looking at the literature. That was, we were not aware of that study beforehand, but as soon as we
01:03:38.920
saw that study, we're like, what? Like this is, this is an extremely alarming study.
01:03:44.460
Yeah. And it sort of validates your numbers because if one pill is putting 40,000 in the urine,
01:03:50.240
as you said, you could assume that there was 4 million in the bloodstream. That's the same order
01:03:56.240
of magnitude as what you found in your chemical analysis, which may or may not be compromised
01:04:01.600
by temperature, which we'll come back to. So why didn't that study get more attention is my question.
01:04:06.980
I mean, honestly, Professor Bill Mitch, great guy that is in the environmental sciences. So he'd been
01:04:13.760
looking at this ranitidine problem himself at Yale University, at Stanford University for 17 years.
01:04:19.960
I mean, his first papers published in 2002 were concerned about where does NDMA come from when
01:04:28.160
it's in drinking water and coming out of wastewater treatment plants. And the irony of how this all
01:04:34.200
came up for him was actually that there's this big environmental problem where they had this rocket
01:04:40.300
fuel plant where NDMA is often a by-product of rocket fuel manufacturing. And they were dumping into
01:04:46.960
a river and all of a sudden there's all this NDMA in drinking water and a lot of attention to NDMA,
01:04:53.940
a very well-known carcinogen. But what they found is that even after they cleaned it up and even after
01:04:58.960
they started looking in other cities, they were still finding low levels of NDMA. It basically sparked
01:05:04.440
the 17 years of research for Bill Mitch and all the various folks that he's been working with and in
01:05:09.480
this field of environmental science of water quality. And I think this has been like this big
01:05:15.180
red button serious problem in a more obscure science than the medical community is used to.
01:05:22.500
You know, I'm sure yourself as a doctor, I try to keep up with a variety of journals or scientific
01:05:28.160
findings, but I don't know how often you're looking up environmental journals.
01:05:32.520
I can tell you the answer to that. It'd be never.
01:05:34.740
Right. Right. And look, I think what we found ourselves in the position at Valisher was adding
01:05:41.740
some new science, some new discoveries that we found, but really we were just connecting the dots
01:05:46.600
over 37 years of research. And what was very clear also in Mitch's paper of that specific study was that
01:05:55.860
there was some sort of missing biological link because there's also been a lot of work which we also
01:06:00.660
recreated, which Bill Mitch did as well, looking at the stomach, just conditions of the human stomach.
01:06:06.360
And you tend to find hundreds of thousands of nanograms of NDMA, which is also very bad being
01:06:12.700
formed by the reninidine molecule. But his study was pointing to the possibility of millions and
01:06:20.080
therefore reninidine forming even outside of the stomach and the body being extremely complex,
01:06:26.220
which drove us at Valisher to look more towards, well, is there a potential biological link here as
01:06:32.800
well? And we identified an enzyme, specifically DDAH1, but this enzyme has also been well-characterized
01:06:40.900
for many years. And what it does is it just grabs onto a molecule and it breaks off this DMA group.
01:06:47.520
So NDMA is the N and the DMA components. And once you break off a DMA, it's very easy to form the NDMA.
01:06:54.440
There's nitrite that freely circles in your body and lots of other ways to make it.
01:06:59.900
And so essentially we looked at this enzyme and did computational modeling to find that seems that
01:07:06.420
the reninidine molecule fits extremely snugly in this enzyme. And that at least gives a potential
01:07:13.260
biological mechanism for forming millions of nanograms throughout the body, even outside of
01:07:18.500
the stomach. We essentially had now that biological link and the chemistry side, and then all the way
01:07:25.220
into the full body clinical study that Bill Mitch did that makes a very compelling story that reninidine
01:07:35.400
So let's talk about the FDA's response to all of this. What was the first date you made public your
01:07:41.740
So we actually confidentially alerted the FDA back in June. I don't recall the exact date.
01:07:48.740
We filed an FDA citizen petition that made our much deeper analysis with the biological link and
01:07:55.220
everything else that we were studying. We filed that September 13th. But we did, even without having
01:08:01.780
the full story yet, we thought the results were so alarming that we did this kind of confidential
01:08:07.520
filing to the FDA. We didn't want to be publicly talking about these kinds of problems if we didn't
01:08:13.440
have the full story. Obviously, cognizant that this drug industry can be extremely litigious. A lot of
01:08:19.080
lawyers don't like it if you're talking about a particular drug badly. So that's when we did the
01:08:24.100
initial alert and continued to analyze this. And then, obviously, the FDA made their own announcement
01:08:30.840
So the September 13th date you filed the citizen's petition was the date that the FDA said that
01:08:36.460
trace amounts, well, actually, I don't have their statement, but do you know exactly what they said?
01:08:41.580
I mean, I remember reading it because at that level, it starts to even get it. Even guys like
01:08:45.500
me will start to see it when the FDA is saying it. But how did they word their response to the
01:08:50.940
So the FDA's statement Friday the 13th, September the 13th, was, and I don't have the exact wording in
01:08:58.560
front of me, but that they had found an impurity in DMA at low levels. I think they made some
01:09:05.340
references to barely exceeding those that's in food. Kind of feels like no big deal, but they're
01:09:11.580
still making an alert and wanted everybody to be aware of that. And us, we've been working for months
01:09:17.460
now on this issue and putting together this citizen's petition that has all the information that we've
01:09:23.840
studied about the chemistry, the biology side of the components, a bunch of citations of as much as we
01:09:30.140
could find in terms of epidemiology. But we also had Lior Bronstein and Morris Lone Kettering, folks
01:09:36.440
there working on the epidemiology, which we thought that's going to be the full story that we wanted to
01:09:41.500
publish as a complete document. And we were actually quite taken back by the fact that the FDA made this
01:09:48.100
kind of announcement on September 13th. And although the citizen petition wasn't complete yet with
01:09:54.520
epidemiological results, we felt that it was very important to publish it, get it on file and have
01:09:59.440
everybody see the full story that includes these very alarming findings on the chemistry and biology and
01:10:06.340
underscoring Bill Mitch's study, which all these things, even just by themselves, are so incredibly
01:10:12.060
concerning that even though we didn't have the epidemiology done yet, we definitely felt should be
01:10:17.900
published. Now, the FDA has the authority to do a lot. I certainly learned what they don't have the
01:10:24.140
authority to do in talking with Catherine Iban. But did they have the authority on September,
01:10:29.920
since it was a Friday, let's give them the weekend to think about it. But on September 16th,
01:10:35.100
that Monday, did they have the authority to pull all forms of ranitidine and Zantac off the market in the
01:10:41.220
United States? I believe they do. They definitely, at the very least, have the authority to request
01:10:46.400
manufacturers recall it. When you hear about recalls, it's almost always voluntary recalls,
01:10:52.920
but the FDA can push for it. Interesting that you mentioned that the following Monday or Tuesday of
01:10:58.240
that week, that's when the first other health system, Canada, so Health Canada made a statement
01:11:05.000
September 17th, that Tuesday, with a very strong message of requesting all companies to stop distributing
01:11:12.420
all forms of ranitidine. And the second line in that statement was, current evidence suggests that
01:11:19.600
NDMA may be present in ranitidine regardless of the manufacturer, which directly underscores what we
01:11:26.580
were finding, that it doesn't matter how it was made or where it was made, just that the drug itself
01:11:32.700
is so incredibly fundamentally unstable that it can directly form NDMA in a whole variety of conditions
01:11:40.300
and should just be taken off the market. Yeah. Well, I'm Canadian. I'll take a little
01:11:45.000
victory lap on the conservative nature of Health Canada. Totally kidding. How many countries besides
01:11:50.140
the great nation to the north of us have followed suit with Canada? So to date, now we're still just
01:11:58.080
only a few weeks away from this September 13th announcement, roughly 30 countries have recalled or
01:12:05.620
banned ranitidine. And I mean, not just places like Italy and France and Germany, but you have Kenya,
01:12:13.900
Libya, Bangladesh, Saudi Arabia, Pakistan. Pakistan actually came out not just recalling all ranitidine
01:12:21.980
products. They actually told all the manufacturers in their country to stop making it, as in stop
01:12:28.020
everything you're doing with anything related to ranitidine. Stop it. And that was in Pakistan.
01:12:33.360
I mean, I just don't even know how to make sense of this, David, to be completely honest with you.
01:12:37.500
So I sort of get Canada's reaction because they were the first to react and they reacted before
01:12:44.340
the FDA had done what they've done over the past few weeks. Do you think a lot of these other countries
01:12:49.960
are just in a herd mentality mode or do you think they've independently taken a look at your data,
01:12:54.820
your petition and come to the same conclusion? I know that's an odd question, but the real question
01:12:59.860
I'm getting at is why has the FDA resisted taking stronger action?
01:13:05.260
Each country has obviously their own health systems. I think a lot of these health systems
01:13:10.040
certainly look towards the FDA, but we were contacted by a number of press that were also
01:13:16.960
talking with the health agencies in their countries. We talked extensively to folks in Switzerland and
01:13:22.560
Germany and Poland, in India, in Russia. And it seemed that quite a few agencies were running their
01:13:30.840
own tests. We know specifically in South Korea, they even published some of those results. They were
01:13:37.560
finding at minimum 2,800 nanograms of NDMA and their worst was 32,000 nanograms of NDMA that was found by
01:13:46.400
South Korea's regulators. And these numbers in of themselves are obviously not good. But I think one of the
01:13:55.560
unfortunate things that happened out of the FDA's original statement is that it made this whole thing
01:14:02.620
just sound like a contamination. And I think you saw this a lot with countries too, is that some of them like
01:14:10.300
Canada, I think realized early on, perhaps seeing our petition, or just looking at some of the data, like Bill
01:14:17.100
Mitch's study, that this is an inherent problem with the drug, and therefore stop all manufacturers, stop all
01:14:23.220
distribution. Whereas some other countries were banning certain manufacturers that maybe they tested, or they had
01:14:30.740
some data suggesting that this manufacturer had some level of contamination in it of NDMA. But even that
01:14:38.820
contamination, maybe we'll talk more about this of contamination versus inherent instability. There's
01:14:43.440
actually a great article in India that talked about this of why has France and Germany banned this
01:14:49.200
substance versus, at the time, India and the United States had not. And then a lot of what they were
01:14:54.520
concluding is that some people are looking at this as a contamination that maybe happens here and
01:14:58.720
there. And some are realizing that the reality that ranitidine is a fundamentally unstable molecule and
01:15:04.760
could certainly cause contamination as a byproduct of being unstable, but has a seemingly very high risk
01:15:11.960
of forming tremendous amounts of NDMA in the human body and should just be taken out completely off the
01:15:16.100
market. So the FDA released a statement in early October that basically said to the effect, hey, we're
01:15:23.260
going to continue to test ranitidine and its products. We're not saying there's nothing wrong here, but they
01:15:28.660
did very specifically challenge your method for testing. And they said specifically, and this I do quote,
01:15:35.780
it is not suitable for testing ranitidine because heating the sample itself generates NDMA. And presumably, they
01:15:43.940
mean heating it to the low temperature of 130 degrees Celsius.
01:15:47.260
Right. So yeah, that exact quote, heating the sample generates NDMA. I mean, they don't mention us
01:15:52.900
specifically, but they do say third party laboratory, which ironically in the press, I don't
01:15:58.800
think they even bothered talking about that. They just inserted the name Balisher. But I think at the
01:16:03.860
very least nicely underscores that even just some heat, which again is benign for practically all these
01:16:10.640
other molecules is enough to generate NDMA. So yes, exactly. We agree. Heat that could be happening
01:16:19.020
anywhere in transit, could be in a hot car or anywhere else, could directly degrade this molecule,
01:16:26.120
not just into falling apart, but into falling apart directly into NDMA.
01:16:30.700
So how do we get to the root of this problem? Because this could end up being the jugular issue.
01:16:34.880
I mean, in many ways, the Zhang and Mitch study suggests you don't need heat. Has the FDA commented
01:16:41.760
Not that I'm aware of. There's plenty of studies out there that look at all sorts of other conditions
01:16:47.480
that degrade ranitidine. Like they're not even looking at in general, they're just saying,
01:16:51.920
okay, here's ranitidine and let's see what happens when we add ozone that is commonly emitted by all
01:16:58.700
sorts of devices and things, or chlorine that you use for cleaning all sorts of things. And it also is
01:17:05.160
used in wastewater treatment plants. And even the reaction mechanisms were specifically ironed out
01:17:10.800
chemically of how ranitidine degrades directly into NDMA with these relatively minor and benign
01:17:18.880
conditions. And certainly the condition that concerned us at Valsher the most was the conditions
01:17:25.720
of the human body. So yes, we, in the introductory paragraph in our citizen petition, also comment on
01:17:33.240
how the FDA method that we use, that was the method available at the time for the analysis of NDMA,
01:17:38.700
we suspect that this 15 minutes of 130 degrees temperature is causing an incredibly efficient
01:17:45.800
reaction of generating NDMA from ranitidine. And so therefore we modified that particular protocol.
01:17:54.380
And I should also say that Valsher, apart from having some great scientists that work with us,
01:17:59.600
we are an ISO accredited facility specifically for the analysis of NDMA. So we modified the protocol,
01:18:06.720
did the proper controls and put down the temperature. So we developed another method still using the GCMS
01:18:14.060
and essentially copying the rest of the FDA protocol, and then bring down the temperature to body
01:18:19.320
temperature. And in this specific way of analysis, we didn't find NDMA in the tablets that we were
01:18:25.820
looking at. And so we used this low temperature version to analyze conditions of the human stomach,
01:18:33.200
actually very similar, almost exactly the same conditions that Bill Mitch was using in his study,
01:18:38.960
and others have used it in other studies before, where essentially we have simulated gastric fluid and nitrite
01:18:44.180
present, which seems to be particularly capable of reacting with ranitidine in your stomach, and is just
01:18:50.660
present in a lot of foods in general and in the human body, even without those foods. So we created those
01:18:57.300
conditions, put one pill of Zantac into essentially 100 milliliters of this kind of stomach fluid,
01:19:04.000
and then using the low temperature system, analyzed that and found very similar numbers as Bill Mitch
01:19:11.220
was finding is in the hundreds of thousands of nanograms of NDMA. So we found up to 300,000 nanograms,
01:19:18.280
Bill Mitch's study found up to 400,000 nanograms. So pretty similar results,
01:19:23.220
a very high formation of NDMA in a body relevant condition.
01:19:28.920
So David, let me just make sure I understand that. So obviously the GCMS gold standard,
01:19:35.220
you can't get around it, you have to be at 130 degrees Celsius in the oven to incubate it,
01:19:40.760
that's going to produce the numbers we've discussed. But you're saying you came up with
01:19:44.060
a different test, which is instead of just taking the pill, crushing it, sticking it into the GCMS,
01:19:49.000
you dump it into a 37 degrees Celsius bath that is modeled after gastric secretion. So it'll have a
01:19:55.700
pH of two, and it'll have this and that other cofactor and enzyme. And you're saying when you
01:20:01.020
took that little soupy bath, you did not have to put it into the GCMS, or you did, but you just ran
01:20:09.380
it at 37 Celsius instead of 130. I want to make sure I understand how you can do a low temp assessment.
01:20:15.260
Yeah. Important question. And that's somewhat of the annoying part of where this discussion has now
01:20:21.380
gotten to with these statements is now the devil's in the details. So, okay, what you described is how
01:20:27.900
we prepared the sample. So the kind of this bath that's emulating stomach conditions. And to analyze
01:20:35.420
that bath, we had to put it still in a GCMS, but now a low temperature profile of the GCMS, which
01:20:42.800
what that does when you lower the temperature in a GCMS is you've gotten less sensitivity.
01:20:49.400
So instead of being sensitive down to 25 nanograms, which is what the FDA protocol gets and that they
01:20:55.440
published and what we were getting in terms of the sensitivity when you use 130 degrees,
01:21:00.780
when you take it down to body temperature, now you're at a hundred nanograms of sensitivity.
01:21:06.660
So a little bit less sensitive. So obviously if you're trying to be a good chemist, you would put
01:21:11.860
it up to 130 degrees and get the highest possible sensitivity, which I'm sure is why the FDA published
01:21:18.960
that protocol at 130 degrees. And again, it's fine for valsartan and almost every other molecule that
01:21:24.460
we've ever looked at. Why is that the case? Why was it fine to go to 130 degrees Celsius with
01:21:30.160
valsartan? Valsartan is not unstable. In other words, the NDMA in valsartan is thought to be a
01:21:36.740
contaminant and not a product of degradation? Exactly. Okay. So can you run the GCMS at 37
01:21:44.820
Celsius? And is that what you're saying? You can, but you can only detect down to a hundred nanograms?
01:21:49.940
Correct. Exactly. So this is splitting hairs here, but who cares when you're dealing with a
01:21:55.280
concentration as high as you're dealing with, right? Exactly. And who cares when there's already
01:22:00.840
a clinical study that was done? We can argue all day about the conditions of the stomach,
01:22:06.400
of various things. You can never recreate biology, right? As soon as we're talking about biology
01:22:11.660
instead of pure chemistry, which is when the data of using the FDA protocol and seeing milligrams of
01:22:18.140
NDMA form from reference powder of ranitidine, that's chemistry analysis. So our conclusion from that
01:22:25.000
is that ranitidine is incredibly unstable, can form milligrams of NDMA in 15 minutes.
01:22:32.180
And there's no other way you could have done this except from the source of the drug itself.
01:22:37.060
As soon as we start talking about biology and stomach conditions, really the ultimate test there
01:22:42.900
is a clinical test where you go through the entire human body, which is exactly what Bill Mitch did at
01:22:50.020
Stanford University. Although did he use 130 degrees Celsius on the GCMS on the urine? Because
01:22:57.780
the real gold standard might be, or I wouldn't say the real gold standard, another elegant test would
01:23:02.500
be you take a person, you give them ranitidine, you collect the urine, and without doing anything,
01:23:07.700
you run that urine at 37 Celsius. And if that showed what Mitchell found, or even close to it,
01:23:16.180
if Mitchell found 40,000, let's just say you found 4,000. Let's just say that the difference between
01:23:21.060
37 Celsius and 130 Celsius on the breakdown product, because again, the question, we don't,
01:23:26.120
what we don't know is, is this person peeing out some byproduct of ranitidine that then further
01:23:31.240
decays to NDMA, or are they just peeing out straight NDMA? And if they are, then the temperature
01:23:37.200
should make very little difference in how much you detect, correct?
01:23:41.140
Right. Actually, when we saw Bill Mitch's study, and also seeing what we were seeing in the GCMS,
01:23:47.940
we called Bill and started asking him about his work and everything else. We were pushing on some
01:23:53.380
of those questions as well. He wasn't using the FDA method, but obviously the devil's in the detail of
01:23:58.980
all these methods. And he went back and did some significant controls to validate these kinds of
01:24:06.500
systems, what's something being created in the instrumentation. And after all of his validation,
01:24:12.280
he was still seeing over these 40,000 nanograms of NDMA.
01:24:17.400
So how confident are you? And again, the answer can't be 100%, or you wouldn't be a scientist,
01:24:23.040
which I know you're a scientist. So how confident are you that grossly elevated levels of NDMA
01:24:30.260
are being made from ranitidine that is not at all an artifact of instrumentation, human error,
01:24:37.780
or most importantly, temperature contamination?
01:24:41.580
Extremely confident. And you hit it on the head that as a proper scientist, I can never be 100% on
01:24:46.780
anything, of course, but the data is just overwhelming. And the other part of this is,
01:24:52.140
as you've mentioned before, this isn't some life-saving drug that there is no alternatives for,
01:24:58.860
where we say, you know what, we're 99% sure, but there's 1% that maybe we're a little bit off here,
01:25:05.300
and people depend on this for their lives. And let's think about that versus the fact that they
01:25:10.980
may cause some cancer over time. That's not the case. Plenty of alternatives, as you've mentioned,
01:25:17.320
this is not a life-saving drug. So I don't see how any of that calculus plays into thinking that
01:25:24.340
this should just be taken off the market. Yeah. And I would add another layer to that,
01:25:28.420
which I guess is why I wanted to speak with you about this, is I have a little bit of a background
01:25:34.000
in risk, in a formal training in risk. In risk training, one of the things you're always taught
01:25:38.680
to look for is asymmetry of risk. So if you have a bet, if you bet somebody $10 on the outcome of
01:25:46.460
something, so you put $10 in, they put $10 in, that's not a very asymmetric bet. You're going to
01:25:51.860
win $10 and therefore walk away with $20, or you're going to lose $10 and lose your money.
01:25:56.380
Those are great bets to make because you have a sense of what the downside is and what the upside
01:26:00.820
is. But what I really struggle with here, David, is this is a very asymmetric bet that the FDA is
01:26:07.260
making. There's a chance you're wrong. There's a chance that in a few years, all of the data will
01:26:14.080
be in, including what I consider arguably the most important data, which will be the human
01:26:18.600
epidemiologic data that tracks the cases and the cohorts. And it will show that Zantac is totally fine.
01:26:25.220
And further chemical analysis will reveal that there is some error in the methodology that you
01:26:30.940
and countless others have made. Doesn't sound like that's the case, but it could be. In that case,
01:26:36.940
the FDA will have been the hero for not recalling the drug. What's the upside in that situation?
01:26:44.060
Conversely, in five years, if the epidemiology or two years or whatever suggests the opposite,
01:26:50.160
which is this totally unnecessary, ubiquitous drug increased by two and a half fold,
01:26:59.040
a risk of cancer of fill in the blank cancer. And when the FDA was notified of this, they did
01:27:05.420
nothing. That's a very asymmetric downside. That downside is infinitely greater than the upside
01:27:12.100
of having done nothing. If anybody at the FDA is listening, I'm sorry if I sound like I'm being a
01:27:18.420
jerk, but I can't help but ask, what is your chief risk officer telling you right now?
01:27:23.480
Because if I was your chief risk officer and I didn't know a thing about biology,
01:27:28.100
I'd be explaining this to you. Where is that discussion, David? Do you know enough about
01:27:32.240
the FDA to understand that? Do they have a chief risk officer?
01:27:34.660
We have had no interaction with the FDA throughout all this, other than our submitting of the citizen
01:27:42.900
petition and seeing what they're saying about us in these statements?
01:27:47.200
Huh. Well, I guess the only thing I can tell you is here's what we've done. We've told that we have
01:27:52.460
three patients in our practice that take Zantac. So the first thing we did when I really figured out
01:27:56.940
how serious this was, which was not on Friday the 13th, by the way, the front of the 13th,
01:28:00.620
I took the FDA's word for it. Stupid Peter. Sorry. But it was a few days later that a little bit
01:28:06.580
more digging made me realize, uh, the FDA might be making a mistake here that we went and scrubbed
01:28:13.580
the medical reconciliations of all our patients, realized three of them took ranitidine. Luckily,
01:28:18.420
none of them regularly. We just called them immediately, said, stop taking this drug. Do
01:28:22.340
not pass go. Do not collect $200. Here's the drug you're going to take instead. Presumably anybody
01:28:27.200
listening to this, I'd feel pretty comfortable suggesting they do the same. What else is there to
01:28:31.580
do? What can citizens do beyond not taking this drug themselves and passing along that insight?
01:28:37.240
Is there anything that the citizens can do with respect to the FDA? I mean, how many citizens
01:28:41.100
petitions does the FDA get a year, by the way? Not sure what that exact number is. It's used for
01:28:46.300
such a variety of different things, but I think they get a few of them a week. But I assume that
01:28:50.960
they're all different, right? I mean, obviously they're all different. I guess what I'm saying is I
01:28:53.620
assume they're of different magnitude of importance. I mean, when a chemical lab of yours stature is
01:28:59.840
submitting this type of data, that's probably different than if I just rung up the FDA and
01:29:05.040
said, hey guys, I noticed when my patient took Crestor, it worked. And when he took resuvastatin,
01:29:09.940
it didn't. That's the type of citizens petition I assume that doesn't go too far. But do you have a
01:29:14.400
sense of how many citizens petitions of your nature and gravity hit their desk? I don't think very many.
01:29:20.560
Do you know how the FDA set the limit at 96 nanograms, by the way? Yeah. So the calculus behind that
01:29:27.320
is basically ensuring that there is less than one cancer case in 100,000 over the course of 70 years.
01:29:36.960
That's an extrapolation from an animal model, correct? Correct. So again, as a scientist,
01:29:41.600
it could be maybe it's not that bad or it could be worse. Humans are not the same as a mouse.
01:29:46.880
Well, David, is there anything else you want to say on this story? I mean, this is,
01:29:50.740
I got to be brutally honest with you. I was a little bit reluctant to speak with you
01:29:54.940
so early in the development of this story because I know that time always brings new insights. But at
01:30:03.700
the same time, I think truthfully, I felt a little bit, a sense of responsibility. I feel fortunate
01:30:08.740
that we have an audience now that is quite large. And if for no other reason than if this message gets
01:30:14.800
to a lot of people who then share it with a lot of people, it can make a difference in at least
01:30:19.780
some people's lives. And again, my calculation is on the asymmetric side of this, if this is wrong,
01:30:26.540
I still feel like we've done no harm in that, at least to a person, meaning we've harmed a company.
01:30:32.100
Let's be clear. If this is wrong, all the companies that make, who makes Zantac, by the way,
01:30:36.660
is it Sanofi? Sanofi bought the rights to in the United States. It's made by a whole bunch of
01:30:41.880
different companies. Right, right. So you've got all the generics and Sanofi that makes the branded,
01:30:45.720
et cetera. I mean, let's be honest. Let's look at it from their standpoint. They're being hurt by this.
01:30:49.780
If this turns out to be wrong, that's potentially devastating financially. I guess I am taking a
01:30:55.600
slightly different risk, which is that the risk of someone switching over to a different H2 blocker
01:31:01.000
or proton pump inhibitor is the worst thing that's going to happen. And the best thing that happens is
01:31:06.260
hopefully some cases of cancer could be averted over the next God knows how long. That might be
01:31:12.040
naive, but that's sort of the reason I wanted to talk with you. But I'm uneasy of the fact that there's
01:31:17.640
more questions than answers, too. One other thing, actually, that I think is important to underscore
01:31:22.540
here and could also play into this overall upside-downside calculus is that the reason this
01:31:30.460
whole issue came up again in the scientific literature in the early 2000s is concern over
01:31:36.360
water quality and NDMA in drinking water. And what we mentioned in the petition that is getting very
01:31:44.320
little attention, unfortunately, is that now that there's all this news and everybody's worried
01:31:50.560
about it for one reason or another of whatever the reading about Zantac and rinidine, if you're
01:31:57.000
throwing it away in the sink, down the toilet, even in trash, which goes to landfills and leachate
01:32:04.120
runoff from that can be treated in chemical methods. All of this is exactly what all these environmental
01:32:10.220
scientists for the last 17 years have been saying is a potential problem because it will form NDMA
01:32:16.080
in the wastewater treatment plant, which then gets used as drinking water. So we certainly feel that
01:32:22.980
if you're making the decision to no longer use a rinidine product, make sure you don't just throw it
01:32:29.740
away or certainly don't throw it down the sink or down the toilet. It needs to be disposed of properly.
01:32:36.640
I mean, essentially, it's got to be disposed of as toxic waste. It's got to be returned to the
01:32:41.700
pharmacy or to all these facilities that do medication disposal. Because another potential
01:32:48.200
downside of all of this is that everybody's dumping it and it's going into the water system
01:32:54.260
and then being converted to high levels of NDMA in drinking water. And now you have another potential
01:32:59.840
crisis. Well, that's a really good point. So again, just to make sure the listener understands
01:33:04.280
exactly what you're talking about. It's one thing to say, wow, this is an issue. I'm going to stop
01:33:08.460
taking my rinididine. But to flush it down the toilet or throw it in the garbage potentially
01:33:13.420
spreads the problem. Now, have you heard of pharmacies accepting samples back and doing
01:33:19.740
whatever is appropriate to dispose of it? I mean, from a practical standpoint, what could somebody do
01:33:24.060
the day they're hearing this? I think specifically, I believe it was Walmart or some of the big
01:33:29.740
pharmacy chains have said that they'll take your product back and even give you a refund.
01:33:35.620
I mean, I don't want to put words in their mouth, but it's something that pharmacies are set up to do
01:33:40.280
and quite sure that a number of them have gone out and said that you can even get a refund for this.
01:33:44.980
Well, David, this may not be the last time we speak because I suspect one, there'll be more to
01:33:49.440
this story, but I suspect that there may be other interesting health issues that crop up as a result of
01:33:55.980
your work. But again, I want to thank you for speaking on very short notice. I want to thank you
01:33:59.400
for speaking with me on a Saturday night. And more than all of that, of course, I want to thank you
01:34:04.640
for the public service that your company does to take care of a problem that honestly, a couple of
01:34:11.480
years ago, I thought was non-existent. And now between your work and certainly that of Catherine's,
01:34:17.140
I've come to really, really doubt the veracity of the FDA and in general, our regulatory environment.
01:34:24.260
I don't say that lightly. I certainly think the FDA is an amazing organization and I think we're
01:34:29.360
richer for it with respect to what most countries go through. I've met many people who work at the
01:34:34.440
FDA. There's great folks there. I want to be clear that I'm not disparaging the FDA, but there's
01:34:39.740
something fundamentally wrong with this type of decision-making. And I don't know where the buck
01:34:43.580
stops, but I'm definitely frustrated by this. And I want to make sure that people are at least
01:34:48.560
armed to make their own decisions, which may differ from mine and yours, but at least they're informed.
01:34:53.220
Absolutely. And I would totally echo that. There's tremendous good that comes out of the FDA and
01:34:58.220
tons of great people that work there. And I certainly hope that these kinds of scenarios will
01:35:04.560
at the very least bring more overall engagement on these issues. And I also not entirely sure what all
01:35:11.600
the decisions are being made here. And I wish that there would be faster action on this specific
01:35:17.520
ranitidine case, but we certainly hope to work with FDA and regulators as a whole on these real
01:35:24.760
problems. I think obviously we have to come to the grasp of the reality that there are problems in the
01:35:31.520
medication system and generics, potentially even brand and all sorts of holes that exist in how the
01:35:39.520
system is now for medications. And we want to be a part of that solution and work together to ensure that
01:35:47.880
every patient is getting a high quality medication.
01:35:52.000
Yeah. Well, thank you very much, David. I appreciate your time and look forward to seeing how this story unfolds.
01:35:57.300
Yeah. Thank you very much, Peter, as well for spending the time on your Saturday night.
01:36:30.720
All with the ID, Peter Atiyah, MD. But usually Twitter is the best way to reach me to share your
01:36:36.440
questions and comments. Now for the obligatory disclaimer, this podcast is for general informational
01:36:41.340
purposes only and does not constitute the practice of medicine, nursing, or other professional health
01:36:46.200
care services, including the giving of medical advice. And note, no doctor patient relationship is
01:36:51.800
formed. The use of this information and the materials linked to the podcast is at the user's own risk.
01:36:57.500
The content of this podcast is not intended to be a substitute for professional medical advice,
01:37:02.220
diagnoses, or treatment. Users should not disregard or delay in obtaining medical advice for any medical
01:37:07.700
condition they have and should seek the assistance of their health care professionals for any such
01:37:12.260
conditions. Lastly, and perhaps most importantly, I take conflicts of interest very seriously. For all of
01:37:18.260
my disclosures, the companies I invest in and or advise, please visit peteratiyahmd.com forward slash about.